Lightlake Therapeutics Inc. to Apply Company’s Patented Technology in the Development of Premenstrual Syndrome Overeating Treatment
January 6, 2012- LONDON -- Lightlake Therapeutics Inc. (OTCBB: LLTP - News) (the “Company” or “Lightlake”), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.
Current studies indicate that about 4 out of 10 women have symptoms of PMS, with many women suffering from PMS experiencing a sharp increase in craving for high-sweet and high-fat foods just before menstruation. This behavior is particularly upsetting among those women who are also overweight, which totals about 20 percent of all women of childbearing age. Endorphins, which are natural opioids, are released when sweets and high fat content foods are consumed, and the endorphins can eventually cause a form of food addiction that can be exacerbated by such disorders as PMS. Dr. David Sinclair of the National Institute for Health and Welfare in Finland and the Chief Scientific Officer of Lightlake previous work in the field of addiction has shown that endorphin-reinforced addictions are gradually weakened and removed with medicines called opioid antagonists.
Lightlake Therapeutics Inc. is currently conducting a randomized double blind placebo controlled trial in Helsinki of its patented treatment for extinguishing binge eating using the opioid antagonist, naloxone. In developing a similar treatment for PMS overeating, Lightlake plans to conduct multi-center clinical trials in the near future to address this global healthcare issue.
About Lightlake Therapeutics, Inc.
Lightlake Therapeutics Inc. is a developing biopharmaceutical company aiming to build a platform of biopharmaceutical solutions to common addictions and related disorders. Currently, the Company is focused on providing a safe, effective and simple treatment for patients who are obese or overweight as a result of Binge Eating Disorder in addition to those patients suffering from Bulimia Nervosa. Lightlake recently acquired patents that will allow it to widen its product pipeline to address patients with addictions to opioid painkillers, methadone, cocaine and amphetamine. The Company anticipates launching a development program for each of these purposes in the future.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward- looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Mr. Kevin Fickle, President
NUWA Group LLC.
Dr. Roger Crystal
Lightlake Therapeutics Inc.